Sökning: onr:"swepub:oai:DiVA.org:oru-111035" >
Patient-Specific Me...
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation
-
- Tobiasson, Magnus (författare)
- Karolinska Institutet
-
- Pandzic, Tatjana (författare)
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
-
- Illman, Johanna (författare)
- Division of Hematology, Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland
-
visa fler...
-
- Nilsson, Lars (författare)
- Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Lund, Sweden
-
- Weström, Simone (författare)
- Karolinska Institutet
-
- Ejerblad, Elisabeth (författare)
- Karolinska Institutet
-
- Olesen, Gitte (författare)
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
-
- Björklund, Andreas (författare)
- Karolinska Institutet
-
- Olsnes Kittang, Astrid (författare)
- Department of Medicine, Haukeland University Hospital, Bergen, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway
-
- Werlenius, Olle (författare)
- Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
-
- Lorentz, Fryderyk (författare)
- Department of Hematology, Norrlands University Hospital, Umeå, Sweden
-
- Rasmussen, Bengt, 1970- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
-
- Cammenga, Jörg (författare)
- Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Lund, Sweden; Division of Molecular Medicine and Gene Therapy, Lund University, Lund, Sweden
-
- Weber, Duruta (författare)
- Department of Hematology, Odense University Hospital, Odense, Denmark
-
- Lindholm, Carolin (författare)
- Department of Hematology, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Huddinge, Centre for Hematology and Regenerative Medicine (HERM), Karolinska Institute, Stockholm, Sweden
-
- Wiggh, Joel (författare)
- Department of Hematology, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Huddinge, Centre for Hematology and Regenerative Medicine (HERM), Karolinska Institute, Stockholm, Sweden
-
- Dimitriou, Marios (författare)
- Karolinska Institutet
-
- Moen, Ann Elin (författare)
- Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
-
- Yip Lundström, Laimei (författare)
- Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
-
- von Bahr, Lena (författare)
- Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
-
- Baltzer-Sollander, Karin (författare)
- Department of Genetics, HUS Diagnostic Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
-
- Jädersten, Martin (författare)
- Karolinska Institutet
-
- Kytölä, Soili (författare)
- Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden
-
- Walldin, Gunilla (författare)
- Department of Medicine, Huddinge, Centre for Hematology and Regenerative Medicine (HERM), Karolinska Institute, Stockholm, Sweden
-
- Ljungman, Per (författare)
- Karolinska Institutet
-
- Groenbaek, Kirsten (författare)
- Department of Hematology, Rigshospitalet, Copenhagen, Copenhagen, Denmark
-
- Mielke, Stephan (författare)
- Karolinska Institutet
-
- Jacobsen, Sten Eirik W. (författare)
- Department of Medicine, Huddinge, Centre for Hematology and Regenerative Medicine (HERM), Karolinska Institute, Stockholm, Sweden
-
- Ebeling, Freja (författare)
- Division of Hematology, Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland
-
- Cavelier, Lucia (författare)
- Department of Genetics, HUS Diagnostic Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
-
- Smidstrup Friis, Lone (författare)
- Department of Hematology, Rigshospitalet, Copenhagen, Copenhagen, Denmark
-
- Dybedal, Ingunn (författare)
- Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
-
- Hellström-Lindberg, Eva (författare)
- Department of Hematology, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Huddinge, Centre for Hematology and Regenerative Medicine (HERM), Karolinska Institute, Stockholm, Sweden
-
visa färre...
-
(creator_code:org_t)
- American Society of Clinical Oncology, 2024
- 2024
- Engelska.
-
Ingår i: Journal of Clinical Oncology. - : American Society of Clinical Oncology. - 0732-183X .- 1527-7755. ; 42:12, s. 1378-1390
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- PURPOSE: Clinical relapse is the major threat for patients with myelodysplastic syndrome (MDS) undergoing hematopoietic stem-cell transplantation (HSCT). Early detection of measurable residual disease (MRD) would enable preemptive treatment and potentially reduced relapse risk.METHODS: Patients with MDS planned for HSCT were enrolled in a prospective, observational study evaluating the association between MRD and clinical outcome. We collected bone marrow (BM) and peripheral blood samples until relapse, death, or end of study 24 months after HSCT. Patient-specific mutations were identified with targeted next-generation sequencing (NGS) panel and traced using droplet digital polymerase chain reaction (ddPCR).RESULTS: Of 266 included patients, estimated relapse-free survival (RFS) and overall survival (OS) rates 3 years after HSCT were 59% and 64%, respectively. MRD results were available for 221 patients. Relapse was preceded by positive BM MRD in 42/44 relapses with complete MRD data, by a median of 71 (23-283) days. Of 137 patients in continuous complete remission, 93 were consistently MRD-negative, 39 reverted from MRD+ to MRD-, and five were MRD+ at last sampling. Estimated 1 year-RFS after first positive MRD was 49%, 39%, and 30%, using cutoff levels of 0.1%, 0.3%, and 0.5%, respectively. In a multivariate Cox model, MRD (hazard ratio [HR], 7.99), WHO subgroup AML (HR, 4.87), TP53 multi-hit (HR, 2.38), NRAS (HR, 3.55), and acute GVHD grade III-IV (HR, 4.13) were associated with shorter RFS. MRD+ was also independently associated with shorter OS (HR, 2.65). In a subgroup analysis of 100 MRD+ patients, presence of chronic GVHD was associated with longer RFS (HR, 0.32).CONCLUSION: Assessment of individualized MRD using NGS + ddPCR is feasible and can be used for early detection of relapse. Positive MRD is associated with shorter RFS and OS (ClinicalTrials.gov identifier: NCT02872662).
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Tobiasson, Magnu ...
-
Pandzic, Tatjana
-
Illman, Johanna
-
Nilsson, Lars
-
Weström, Simone
-
Ejerblad, Elisab ...
-
visa fler...
-
Olesen, Gitte
-
Björklund, Andre ...
-
Olsnes Kittang, ...
-
Werlenius, Olle
-
Lorentz, Frydery ...
-
Rasmussen, Bengt ...
-
Cammenga, Jörg
-
Weber, Duruta
-
Lindholm, Caroli ...
-
Wiggh, Joel
-
Dimitriou, Mario ...
-
Moen, Ann Elin
-
Yip Lundström, L ...
-
von Bahr, Lena
-
Baltzer-Sollande ...
-
Jädersten, Marti ...
-
Kytölä, Soili
-
Walldin, Gunilla
-
Ljungman, Per
-
Groenbaek, Kirst ...
-
Mielke, Stephan
-
Jacobsen, Sten E ...
-
Ebeling, Freja
-
Cavelier, Lucia
-
Smidstrup Friis, ...
-
Dybedal, Ingunn
-
Hellström-Lindbe ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of Clini ...
- Av lärosätet
-
Örebro universitet
-
Karolinska Institutet